Erlotinib Promising for Cancer Prevention in FAP
Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.
Medscape Medical News
source https://www.medscape.com/viewarticle/979611?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/979611?src=rss
Comments
Post a Comment